Skip header and navigation

1 records – page 1 of 1.

Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.

https://arctichealth.org/en/permalink/ahliterature144775
Source
J Urol. 2010 May;183(5):1892-8
Publication Type
Article
Date
May-2010
Author
Sender Herschorn
Lynn Stothers
Kevin Carlson
Blair Egerdie
Jerzy B Gajewski
Peter Pommerville
Jane Schulz
Sidney Radomski
Harold Drutz
Jack Barkin
Fran Paradiso-Hardy
Author Affiliation
Department of Surgery/Urology, University of Toronto, Toronto, Ontario, Canada. s.herschorn@utoronto.ca
Source
J Urol. 2010 May;183(5):1892-8
Date
May-2010
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Canada - epidemiology
Chi-Square Distribution
Double-Blind Method
Drug Administration Schedule
Female
Humans
Incidence
Male
Mandelic Acids - administration & dosage - adverse effects
Middle Aged
Muscarinic Antagonists - administration & dosage - adverse effects
Questionnaires
Quinuclidines - administration & dosage
Severity of Illness Index
Tetrahydroisoquinolines - administration & dosage
Treatment Outcome
Urinary Bladder, Overactive - drug therapy
Xerostomia - chemically induced - epidemiology
Abstract
Although antimuscarinic treatment is indicated for overactive bladder, many patients discontinue it because of dry mouth. Of available antimuscarinics oxybutynin is associated with the highest dry mouth rate. We compared the safety and tolerability of 5 mg solifenacin vs 15 mg oxybutynin immediate release.
At 12 Canadian centers a total of 132 patients with overactive bladder symptoms (greater than 1 urgency episode per 24 hours, and 8 or greater micturitions per 24 hours) were randomized to 5 mg solifenacin once daily or 5 mg oxybutynin 3 times daily for 8 weeks. The primary end point was the incidence and severity of dry mouth reported after direct questioning. Efficacy end points (3-day diary documented changes in urgency, frequency, incontinence, nocturia and voided volume), and changes on the Patient Perception of Bladder Condition scale and the Overactive Bladder Questionnaire were evaluated secondarily.
Of patients on solifenacin vs oxybutynin immediate release 35% vs 83% reported dry mouth (p
Notes
Comment In: Nat Rev Urol. 2010 Jun;7(6):30320545037
PubMed ID
20303119 View in PubMed
Less detail